Please assess the completion status of the following clinical trial:

Trial Title: OMO-1 in Solid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 18 years~* Provision of signed and dated, written informed consent.~* Histological or cytological confirmation of locally advanced, unresectable or metastatic solid malignancy.~* Performance status: Eastern Co-operative Oncology Group (ECOG) ≤1 and life expectancy ≥3 months.~* Ability to swallow and retain oral medication.~* Adequate organ functions.~* Females of child-bearing potential:~  * Must use a highly effective method contraceptive measures during the study and for 1 month after the last dose of OMO 1.~ * Must not be breast feeding.~ * Must have a negative pregnancy test prior to start of dosing.~* Sexually active male patients must be willing to use barrier contraception~Exclusion Criteria:~* Patients receiving other cancer therapy, or other investigational product apart from the combination agent(s) described in the relevant combination modules.~* Patients who have received radiotherapy for the primary tumour within 1 week from the screening visit.~* Patients receiving medications predominantly metabolized by CYP2B6.~* Patients receiving cannabinoid substances.~* Patients receiving St John's Wort.~* Patients receiving medications that are known to have potent aldehyde oxidase (AO) inhibitory activity.~* Patients with prior splenectomy.~* Patients testing positive for human immunodeficiency virus (HIV) infection, hepatitis B based on findings of persistent hepatitis B virus surface antigen (HBsAg) or other serology test, hepatitis C virus (HCV) or Epstein-Barr Virus (EBV) infection.~* Patients with current, or a history of uveitis.~* Patients with any known uncontrolled inter-current illness including ongoing or active infections, symptomatic congestive heart failure, conditions that could adversely be affected by hypertension or tachycardia, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Patients with a history or clinical evidence of neoplastic central nervous system (CNS) involvement if not stable for 9 weeks prior to the first dose of study treatment.~* Patients with major and/or planned surgery within 12 weeks of the first dose of study treatment.~* Patients with any known severe allergies (e.g., anaphylaxis) to any active or inactive ingredients in OMO-1.~* Patients with nephrolithiasis.~* Patients with current, or a history of any seizure or seizure disorder. This includes receiving, or having received, seizure threshold-raising medication for the treatment of epilepsy.~In addition to the main core eligibility criteria, Module specific eligibility criteria include:~Module 1:~Patient recruited into the paired biopsy cohorts of Part A must have:~* at least 1 lesion suitable for biopsy.~* tumours that are MET gene amplified and/or mutated.~* had no prior therapy with a selective MET inhibitor.~Patients recruited into Part B cohorts must have:~* tumours that are MET gene amplified and/or mutated.~* at least one lesion, not previously irradiated, that can be accurately measured at baseline.~* had no prior therapy with a selective MET inhibitor.~* no coinciding malignancy that would impact on survival.~* no metastasis limited to the bone only.~Module 2:~Patients recruited into Part A and Part B cohorts must have:~* tumours that are EGFR gene mutant that are currently progressing on treatment with a small molecule EGFR-TKI. Enrolment must be restricted to patients that are resistant to all relevant EGFR TKI therapy according to their tumour mutated status.~* received the EGFR-TKI as monotherapy for at least 12 weeks.~* tolerated their current dose of EGFR-TKI for at least 12 weeks.~* tumours that are MET gene amplified.~* had no prior therapy with a selective MET inhibitor.~* had no prior EGFR-TKI treatment of \>2 lines.~* no past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.~* no significant GI disorders with diarrhoea as a major symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade \>1 diarrhoea of any aetiology at the enrolment.~* no contra-indications (as per the relevant medication package insert) for therapy with the EGFR-TKI routinely used by their oncology unit.~In addition, patients recruited into Module 2 Part B cohorts must have:~* at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI and which is suitable for accurate repeated assessment.~* no coinciding malignancy that would impact on survival.~* no metastasis limited to the bone only.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Module 1 Monotherapy Multiple Ascending Dose (Type: EXPERIMENTAL): Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
- Module 1 Monotherapy Paired Biopsy (Type: EXPERIMENTAL): Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
- Module 1 Monotherapy Expansion Cohort(s) (Type: EXPERIMENTAL): Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
- Module 2 Combination with EGFR-TKI Multiple Ascending Dose (Type: EXPERIMENTAL): Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
- Module 2 Combination with EGFR-TKI Paired Biopsy (Type: EXPERIMENTAL): Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
- Module 2 Combination with EGFR-TKI Expansion Cohort (Type: EXPERIMENTAL): Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy